Last reviewed · How we verify
NCT06571864: AL38
AL Amyloidosis and Anti-CD38-Daratunumab
NA trial testing Anti-CD38 Monoclonal Antibody in Amyloidosis in 14 participants. Completed in 2 February 2024.
2 January 2024
Quick facts
| Lead sponsor | University of Turin, Italy |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 2 January 2022 |
| Primary completion | 2 January 2024 |
| Estimated completion | 2 February 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Anti-CD38 Monoclonal Antibody — full drug profile →
Conditions studied
- Amyloidosis — all drugs for Amyloidosis →
Sponsor
University of Turin, Italy
Who can join
18 and older, any sex, with Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
AL Amyloidosis and anti-CD38
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06571864
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anti-CD38 Monoclonal Antibody
Trials testing the same drug.
- NCT07090954 — A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Mul · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Amyloidosis
Currently open trials in the same condition.
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06974877 — Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure · Phase 1 · recruiting
- NCT07081646 — A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido · Phase 1, PHASE2 · recruiting
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
Other University of Turin, Italy trials
Trials by the same sponsor.
- NCT06493188 — Low VS High-fidelity Interprofessional Simulation for ABG Skills Acquisition · NA · not yet recruiting
- NCT07418489 — Biotics Intervention Oriented to Rescue From Environmental Pollution Inflammatory Responses · NA · enrolling by invitation
- NCT07311291 — The Effect of Different Hemostatic Agents on Hemorrhage Control, Pain and Quality of Life After Endodontic Microsurgery. · NA · completed
- NCT06904963 — Efficacy of Oral Hygiene Instructions Carried Out Using an Intra-oral Scanner · NA · completed
- NCT07047261 — Efficacy of a Xanthan-based Chlorhexidine Gel in the Treatment of Peri-implant Mucositis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06571864 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Turin, Italy
- Last refreshed: 26 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06571864.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing